Welcome!

News Feed Item

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Sickle Cell Disease Global Clinical Trials Review, H2, 2014" provides data on the Sickle Cell Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sickle Cell Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sickle Cell Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Sickle Cell Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Sickle Cell Disease 25
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Sickle Cell Disease Therapeutics Clinical Trials 33
Prominent Drugs 35
Latest Clinical Trials News on Sickle Cell Disease 36
Jun 16, 2014: Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
Novartis AG 37
Clinical Trial Overview of Novartis AG 37
Eli Lilly and Company 38
Clinical Trial Overview of Eli Lilly and Company 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Prolong Pharmaceuticals 40
Clinical Trial Overview of Prolong Pharmaceuticals 40
HemaQuest Pharmaceuticals, Inc. 41
Clinical Trial Overview of HemaQuest Pharmaceuticals, Inc. 41
Selexys Pharmaceuticals Corporation 42
Clinical Trial Overview of Selexys Pharmaceuticals Corporation 42
Ikaria Inc. 43
Clinical Trial Overview of Ikaria Inc. 43
Emmaus Life Sciences, Inc. 44
Clinical Trial Overview of Emmaus Life Sciences, Inc. 44
Baxter International Inc. 45
Clinical Trial Overview of Baxter International Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Heart, Lung, and Blood Institute 46
Clinical Trial Overview of National Heart, Lung, and Blood Institute 46
Assistance Publique - Hopitaux de Paris 49
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 49
HaEmek Medical Center 50
Clinical Trial Overview of HaEmek Medical Center 50
Cincinnati Children's Hospital Medical Center 51
Clinical Trial Overview of Cincinnati Children's Hospital Medical Center 51
Duke University 52
Clinical Trial Overview of Duke University 52
Emory University 53
Clinical Trial Overview of Emory University 53
National Institutes of Health Clinical Center 54
Clinical Trial Overview of National Institutes of Health Clinical Center 54
Baylor College of Medicine 55
Clinical Trial Overview of Baylor College of Medicine 55
Children's Hospital & Research Center Oakland 56
Clinical Trial Overview of Children's Hospital & Research Center Oakland 56
Five Key Clinical Profiles 57
Appendix 99
Abbreviations 99
Definitions 99
Research Methodology 100
Secondary Research 101
About GlobalData 101
Contact Us 101
Disclaimer 101
Source 102

List of Tables
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Sickle Cell Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Sickle Cell Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 37
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 38
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 39
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Prolong Pharmaceuticals, 2014* 40
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HemaQuest Pharmaceuticals, Inc., 2014* 41
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Selexys Pharmaceuticals Corporation, 2014* 42
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ikaria Inc., 2014* 43
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emmaus Life Sciences, Inc., 2014* 44
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2014* 45
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 46
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 49
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HaEmek Medical Center, 2014* 50
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Cincinnati Children's Hospital Medical Center, 2014* 51
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 52
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 53
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institutes of Health Clinical Center, 2014* 54
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 55
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Hospital & Research Center Oakland, 2014* 56

List of Figures
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
GlobalData Methodology 100

Read the full report:
Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
It’s 2016: buildings are smart, connected and the IoT is fundamentally altering how control and operating systems work and speak to each other. Platforms across the enterprise are networked via inexpensive sensors to collect massive amounts of data for analytics, information management, and insights that can be used to continuously improve operations. In his session at @ThingsExpo, Brian Chemel, Co-Founder and CTO of Digital Lumens, will explore: The benefits sensor-networked systems bring to ...
Much of IT terminology is often misused and misapplied. Modernization and transformation are two such terms. They are often used interchangeably even though they mean different things and have very different connotations. Indeed, it is somewhat safe to assume that in IT any transformative effort is likely to also have a modernizing effect, and thus, we can see these as levels of improvement efforts. However, many businesses are being led to believe if they don’t transform now they risk becoming ...
SYS-CON Events announced today the Enterprise IoT Bootcamp, being held November 1-2, 2016, in conjunction with 19th Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA. Combined with real-world scenarios and use cases, the Enterprise IoT Bootcamp is not just based on presentations but with hands-on demos and detailed walkthroughs. We will introduce you to a variety of real world use cases prototyped using Arduino, Raspberry Pi, BeagleBone, Spark, and Intel Edison. Y...
When building large, cloud-based applications that operate at a high scale, it’s important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. “Fly two mistakes high” is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Lee...
Large scale deployments present unique planning challenges, system commissioning hurdles between IT and OT and demand careful system hand-off orchestration. In his session at @ThingsExpo, Jeff Smith, Senior Director and a founding member of Incenergy, will discuss some of the key tactics to ensure delivery success based on his experience of the last two years deploying Industrial IoT systems across four continents.
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...
Identity is in everything and customers are looking to their providers to ensure the security of their identities, transactions and data. With the increased reliance on cloud-based services, service providers must build security and trust into their offerings, adding value to customers and improving the user experience. Making identity, security and privacy easy for customers provides a unique advantage over the competition.
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
"Tintri was started in 2008 with the express purpose of building a storage appliance that is ideal for virtualized environments. We support a lot of different hypervisor platforms from VMware to OpenStack to Hyper-V," explained Dan Florea, Director of Product Management at Tintri, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"Avere Systems is a hybrid cloud solution provider. We have customers that want to use cloud storage and we have customers that want to take advantage of cloud compute," explained Rebecca Thompson, VP of Marketing at Avere Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SaaS companies can greatly expand revenue potential by pushing beyond their own borders. The challenge is how to do this without degrading service quality. In his session at 18th Cloud Expo, Adam Rogers, Managing Director at Anexia, discussed how IaaS providers with a global presence and both virtual and dedicated infrastructure can help companies expand their service footprint with low “go-to-market” costs.